119 related articles for article (PubMed ID: 8721280)
1. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine.
Otani K; Ishida M; Kaneko S; Mihara K; Ohkubo T; Osanai T; Sugawara K
Ther Drug Monit; 1996 Apr; 18(2):164-7. PubMed ID: 8721280
[TBL] [Abstract][Full Text] [Related]
2. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.
Mihara K; Otani K; Ishida M; Yasui N; Suzuki A; Ohkubo T; Osanai T; Kaneko S; Sugawara K
Ther Drug Monit; 1997 Feb; 19(1):43-5. PubMed ID: 9029745
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of trazodone metabolism by thioridazine in humans.
Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Ishida M; Mihara K; Kondo T; Sugawara K; Fukushima Y
Ther Drug Monit; 1995 Aug; 17(4):333-5. PubMed ID: 7482685
[TBL] [Abstract][Full Text] [Related]
4. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.
Mihara K; Yasui-Furukori N; Kondo T; Ishida M; Ono S; Ohkubo T; Osanai T; Sugawara K; Otani K; Kaneko S
Ther Drug Monit; 2002 Aug; 24(4):563-6. PubMed ID: 12142643
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.
Mihara K; Kondo T; Suzuki A; Yasui-Furukori N; Ono S; Otani K; Kaneko S
Pharmacol Toxicol; 2001 May; 88(5):267-70. PubMed ID: 11393588
[TBL] [Abstract][Full Text] [Related]
6. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
Ishida M; Otani K; Kaneko S; Ohkubo T; Osanai T; Yasui N; Mihara K; Higuchi H; Sugawara K
Int Clin Psychopharmacol; 1995 Sep; 10(3):143-6. PubMed ID: 8675966
[TBL] [Abstract][Full Text] [Related]
7. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.
Otani K; Tybring G; Mihara K; Yasui N; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
Eur J Clin Pharmacol; 1998 Jan; 53(5):347-9. PubMed ID: 9516035
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
Mihara K; Otani K; Suzuki A; Yasui N; Nakano H; Meng X; Ohkubo T; Nagasaki T; Kaneko S; Tsuchida S; Sugawara K; Gonzalez FJ
Psychopharmacology (Berl); 1997 Sep; 133(1):95-8. PubMed ID: 9335086
[TBL] [Abstract][Full Text] [Related]
9. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression.
Otani K; Yasui N; Kaneko S; Ohkubo T; Osanai T; Sugawara K
Int Clin Psychopharmacol; 1996 Mar; 11(1):55-7. PubMed ID: 8732315
[TBL] [Abstract][Full Text] [Related]
10. Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC.
Vatassery GT; Holden LA; Hazel DK; Dysken MW
Clin Biochem; 1997 Mar; 30(2):149-53. PubMed ID: 9127697
[TBL] [Abstract][Full Text] [Related]
11. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions.
Karhu D; Groenewoud G; Potgieter MA; Mould DR
J Clin Pharmacol; 2010 Dec; 50(12):1438-49. PubMed ID: 20173086
[TBL] [Abstract][Full Text] [Related]
12. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
Wen B; Ma L; Rodrigues AD; Zhu M
Drug Metab Dispos; 2008 May; 36(5):841-50. PubMed ID: 18238857
[TBL] [Abstract][Full Text] [Related]
13. High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector.
Ohkubo T; Osanai T; Sugawara K; Ishida M; Otani K; Mihara K; Yasui N
J Pharm Pharmacol; 1995 Apr; 47(4):340-4. PubMed ID: 7791034
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone.
Otani K; Mihara K; Yasui N; Ishida M; Kondo T; Tokinaga N; Ohkubo T; Osanai T; Sugawara K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jan; 21(1):239-44. PubMed ID: 9075270
[TBL] [Abstract][Full Text] [Related]
15. Trazodone treatment increases plasma prolactin concentrations in depressed patients.
Otani K; Yasui N; Kaneko S; Ishida M; Ohkubo T; Osanai T; Sugawara K; Fukushima Y
Int Clin Psychopharmacol; 1995 Jun; 10(2):115-7. PubMed ID: 7673654
[TBL] [Abstract][Full Text] [Related]
16. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Maes M; Westenberg H; Vandoolaeghe E; Demedts P; Wauters A; Neels H; Meltzer HY
J Clin Psychopharmacol; 1997 Oct; 17(5):358-64. PubMed ID: 9315986
[TBL] [Abstract][Full Text] [Related]
17. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.
Rotzinger S; Fang J; Baker GB
Drug Metab Dispos; 1998 Jun; 26(6):572-5. PubMed ID: 9616194
[TBL] [Abstract][Full Text] [Related]
18. Effect of dosage and route of administration of trazodone on cerebral concentration of 1-m-chlorophenylpiperazine in rats. Kinetics of trazodone biotransformation in rats.
Rurak A; Melzacka M
Pol J Pharmacol Pharm; 1983; 35(3):241-7. PubMed ID: 6622303
[TBL] [Abstract][Full Text] [Related]
19. Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography.
Caccia S; Ballabio M; Fanelli R; Guiso G; Zanini MG
J Chromatogr; 1981 Jun; 210(2):311-8. PubMed ID: 7263792
[TBL] [Abstract][Full Text] [Related]
20. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding.
Odagaki Y; Toyoshima R; Yamauchi T
J Psychopharmacol; 2005 May; 19(3):235-41. PubMed ID: 15888508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
